04.15.24 -- Getting To Know MAM, The New Quality Control Strategy On The Block

Drug developers must understand the latest trends in microbial fermentation. By leveraging innovative methods and technologies, developers can unlock new opportunities and improve patient outcomes.

Determining ideal media composition for a bacteria is critical because it fosters a satisfactory grow rate, allowing the bacteria to reach the required growth yield.

Drug product stability may be seriously compromised if mannitol completes crystallization during storage rather than during the freezing step in the lyophilization process.

New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings.

The journey of a novel bioconjugate into clinic is complex and uncertain. Explore the challenges of moving a bioconjugate candidate from early development into clinic.

Review the technologies underpinning sensors utilized in dissolved CO₂ measurement devices and determine which sensors are appropriate for your application.

The pathway from early clinical phases to commercial is not straightforward, particularly for complex sterile injectable products. It is important to have a wide range of specialized capabilities to keep pace with the rapidly evolving market. Global Pfizer experts will explore key aspects of the sterile injectable journey, including factors to consider during the development and tech transfer stages. Click here to learn more.

As we expand our mammalian capacity across the manufacturing network, updates on completion dates and capacity availability are presented in the session.

Learn how our parallel development service works seamlessly with our existing antibody capabilities, helping to accelerate your ADC program and reach market faster.

Leverage robust development strategies and enable an optimized process for mAb development and manufacturing, efficiency and speed with exceptional quality, and high titers with lower-cost workflows for maximum ROI.